Atyr Pharma will meet with the U.S. Food and Drug Administration (FDA) next month to review results from the Phase 3 EFZO-FIT clinical trial and discuss the path forward for efzofitimod as a treatment for pulmonary sarcoidosis. The meeting follows a company announcement last year that the trial…
Search results for:
A bipartisan group of U.S. lawmakers is joining forces to form a new team — the Congressional Sarcoidosis Caucus — to help lead a nationwide fight against sarcoidosis, a rare disease that can affect any of the body’s organs. The newly formed caucus will work to raise awareness about…
The Sarcoidosis Research Institute (SRI) will host a free virtual conference in April aimed at empowering people affected by sarcoidosis. The conference, called Empowering the Patient Journey: Living Well with Sarcoidosis, will take place from 1 p.m. to 5 p.m. EST on April 25. It will feature expert-led…
The global burden of pulmonary sarcoidosis and other interstitial lung diseases (ILDs) increased significantly between 1990 and 2023, with rises in new and total cases, deaths, and loss of healthy years, a study showed. The data also showed that the burden varies by region and is highest among adults…
Receiving a high dose of Priovant Therapeutics’ oral treatment candidate brepocitinib in a clinical trial led to substantial reductions in symptom severity for all participants with cutaneous sarcoidosis, in which the disease affects the skin, new data show. Further, no serious side effects were reported in the…
A new artificial intelligence (AI) model predicted sudden cardiac death (SCD) risk more accurately than current clinical guidelines in people with cardiac sarcoidosis, according to a U.S. study. The AI model, called Multimodal Artificial Intelligence for Ventricular Arrhythmia Risk Stratification in Cardiac Sarcoidosis (MAARS-CS), estimates risk using heart MRI…
The Foundation for Sarcoidosis Research (FSR) has announced $400,000 in new funding to support early-stage research projects aimed at improving the diagnosis, treatment, and management of the rare inflammatory disease. The funding is divided into four grants of $100,000 each. Two were awarded to projects focused on cardiac…
Menopause is something that affects just about half of the population eventually. But for many, it remains a giant question mark, or a whole bunch of questions. In that way, it resembles sarcoidosis. There are the basic questions about it: Am I currently going through it? What stage am…
The Foundation for Sarcoidosis Research (FSR) has welcomed seven new institutions, including its first international member, into its FSR Global Sarcoidosis Clinic Alliance (FSR-GSCA), expanding a growing network of members dedicated to improving care for people living with sarcoidosis. Launched in 2022, the FSR-GSCA brings together leading…